Acción 300254 SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas ShanXi C&Y Pharmaceutical Group Co.,LTD.

Acciones

300254

CNE1000016D0

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 07/06/2024 		Varia. Cinco días. Varia. 1 de enero.
8,27 CNY +2,99 % Gráfico intradía de ShanXi C&Y Pharmaceutical Group Co.,LTD. -10,11 % -14,12 %
12/04 ShanXi C&Y Pharmaceutical Group Co.,LTD. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
18/03 ShanXi C&Y Pharmaceutical Group Co. presenta los resultados del ejercicio finalizado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 184.999997 million in funding
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. announced that it expects to receive CNY 105 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
C&Y Pharmaceutical Raises $15.5 Million in Private Placement
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it has received CNY 109.999995 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 130 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors
ShanXi C&Y Pharmaceutical Group Co., Ltd. and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing.
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
Hangzhou Pollen Group Company Limited announced that it has received CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300254
  4. Noticias ShanXi C&Y Pharmaceutical Group Co.,LTD.
  5. Otros idiomas